Radiopharmaceuticals Third-Party Logistics Market Dynamics and Future Growth Prospects
The global radiopharmaceuticals third-party logistics market size was estimated at USD 0.9 billion in 2025 and is projected to reach USD 2.9 billion by 2033, growing at a CAGR of 15.3% from 2026 to 2033. The radiopharmaceuticals third-party logistics (3PL) market is experiencing strong growth due to a combination of operational and clinical factors associated with the transportation and handling of radioactive diagnostic and therapeutic products. These materials require highly specialized logistics capabilities, including strict temperature control, radiation safety protocols, regulatory compliance, and precise coordination to ensure that products are delivered safely and within narrow time windows.
A major factor contributing to market expansion is the time-sensitive nature of radiopharmaceuticals, as many radioisotopes have ultra-short half-lives that begin to decay rapidly after production. This characteristic makes highly synchronized, just-in-time delivery models essential to preserve product efficacy and minimize losses caused by radioactive decay. Logistics providers must therefore maintain robust transportation networks, specialized packaging solutions, and real-time tracking systems to ensure timely and secure delivery to hospitals, imaging centers, and treatment facilities.
In addition, the expanding adoption of nuclear medicine, molecular imaging, and theranostics is significantly increasing both shipment volumes and delivery frequency, intensifying demand for specialized and highly reliable logistics services. The growing use of radiopharmaceuticals in positron emission tomography (PET), single-photon emission computed tomography (SPECT), and targeted cancer therapies is creating new opportunities for logistics providers with expertise in handling radioactive materials. Furthermore, the expanding pipeline of radiopharmaceutical-based diagnostics and targeted therapies continues to reinforce this trend, supporting long-term growth as healthcare providers increasingly rely on advanced nuclear medicine solutions for precision diagnosis and treatment.
Key Market Trends & Insights
• North America radiopharmaceuticals third-party logistics market held the largest share of 38.1% of the global market in 2025. The region’s leading position is supported by its advanced nuclear medicine infrastructure, strong presence of radiopharmaceutical manufacturers, well-established cold chain and hazardous materials transportation networks, and growing adoption of molecular imaging and targeted radionuclide therapies. In addition, favorable regulatory frameworks and significant investments in oncology and precision medicine continue to strengthen demand for specialized logistics services across North America.
• The radiopharmaceuticals third-party logistics market in the U.S. is expected to grow significantly over the forecast period. Growth is driven by increasing utilization of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) procedures, expanding availability of theranostic treatments, and a robust pipeline of radiopharmaceutical diagnostics and therapeutics. The need for highly coordinated, time-sensitive transportation solutions for isotopes with short half-lives is further accelerating the adoption of specialized third-party logistics providers in the country.
• Based on type, the diagnostic radiopharmaceuticals segment held the highest market share in 2025. This segment’s dominance is attributed to the widespread use of radiotracers in imaging procedures for early disease detection, treatment planning, and monitoring of clinical outcomes. The high frequency of diagnostic procedures and consistent demand for timely delivery contribute significantly to the segment’s leading position.
• Based on service, the contract manufacturing segment held the highest market share in 2025. This segment plays an essential role in supporting radiopharmaceutical production by providing specialized manufacturing capabilities, quality assurance, regulatory compliance, and integrated logistics services that help streamline commercialization and distribution processes.
• Based on source, the microbial segment held the highest market share in 2025. The segment’s strong performance is supported by the increasing use of microbial-derived materials and production systems in specialized radiopharmaceutical development and associated bioprocessing applications.
• Based on workflow, the commercial segment held the highest market share in 2025. The segment benefits from the growing commercialization of approved radiopharmaceutical products and the increasing volume of routine shipments to hospitals, imaging centers, and treatment facilities worldwide.
• Based on therapeutic area, the oncology segment held the highest market share in 2025. The segment’s dominance is driven by the extensive use of radiopharmaceuticals in cancer diagnosis, staging, and targeted treatment, along with the rising global burden of cancer and growing adoption of precision oncology approaches.
Looking for more specific insights? Customize this report to suite your business needs
Key Radiopharmaceuticals Third-Party Logistics Company Insights
The key players operating across the radiopharmaceuticals third-party logistics market are increasingly adopting a range of strategic initiatives, including service launches, mergers and acquisitions, partnerships, agreements, and geographic expansions, to strengthen their competitive positions and expand their service capabilities. These strategies enable companies to enhance their specialized transportation networks, improve regulatory compliance, increase operational efficiency, and better address the complex requirements associated with handling radioactive diagnostic and therapeutic products. As the demand for time-sensitive and highly regulated logistics services continues to grow, market participants are focusing on building integrated solutions that combine secure packaging, real-time shipment tracking, temperature control, radiation safety, and just-in-time delivery.
For instance, in April 2026, Telix Pharmaceuticals and Regeneron Pharmaceuticals established a collaboration to co-develop and commercialize innovative radiopharmaceutical therapies. This partnership combines Telix Pharmaceuticals’ expertise in radiopharmaceutical development, manufacturing capabilities, and global supply chain operations with Regeneron Pharmaceuticals’ strengths in biologic drug research, particularly in bispecific antibody technology. By leveraging complementary capabilities, the collaboration is expected to accelerate the advancement of targeted radiopharmaceutical treatments and support broader commercialization efforts. Such strategic alliances highlight the increasing importance of integrated manufacturing and logistics capabilities in ensuring the efficient production, distribution, and delivery of next-generation radiopharmaceutical therapies to healthcare providers worldwide.
Key Radiopharmaceuticals Third-Party Logistics Companies:
The following key companies have been profiled for this study on the radiopharmaceuticals third-party logistics market.
• Life Couriers
• UPS
• World Courier (Cencora)
• American Expediting
• AirNet II LLC
• GTA Air Inc.
• Lab Carriers
• Kalitta Charters
• NAF Pharma
• PHSE S.r.l.
Grand View Research offers
√ Focused market intelligence reports on specific geographies or high-growth segments.
√ Extended forecast timelines for long-term planning.
√ Competitor Benchmarking and Supply Chain Analysis
√ Inclusion of regulatory and policy assessments.
√ Inclusion of custom data models, KPIs, or applications unique to your business
√ Specific high-impact Data Decks and Tables to support effective decision making
And much more…
Looking for a report customized to your requirements? Explore our Custom Research Offering
Comments
Post a Comment